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Abstract
Background: Peroxisome proliferator-activated receptor gamma (PPARc), a nuclear receptor, has been implicated playing a
role in the development of inflammatory bowel disease (IBD). However, previous studies evaluating the association
between the PPARc2 Pro12Ala polymorphism and IBD are inconsistent. We performed a meta-analysis to determine
whether the PPARc2 Pro12Ala mutation was associated with the presence of IBD.
Methods and Findings: Electronic databases were searched for case-control studies evaluating the association between the
Pro12Ala mutation and the presence of IBD. Effects were summarized with the methods recommended by the Cochrane
Collaboration. A total of 7 studies including 1002 ulcerative colitis (UC) cases, 1090 Crohn `s disease (CD) cases and 1983
controls were involved in this meta-analysis. In the overall analysis, no significant association of this polymorphism with UC
or CD was found. In the subgroup analyses in different populations, AlaAla genotype seemed to protect the European
Caucasian population against the development of CD (Pro vs Ala: OR=1.135, 95%CI=0.951–1.354, P=0.162, Bon=1.000;
ProPro vs ProAla: OR=1.042, 95%CI=0.852–1.273, P=0.690, Bon=1.000; ProPro vs AlaAla: OR=2.379, 95%CI=1.110–5.100,
P=0.026, Bon=0.156; ProAla vs AlaAla: OR=2.315, 95%CI=1.064–5.037, P=0.034, Bon=0.204; Pro homozygotes vs Ala
positives: OR=1.094, 95%CI=0.899–1.330, P=0.371, Bon=1.000; Pro positives vs Ala homozygotes: OR=2.360,
95%CI=1.103–5.053, P=0.027, Bon=0.162; heterozygotes vs all homozygotes: OR=0.976, 95%CI=0.799–1.192, P=0.809,
Bon=1.000). There was no significant association of this polymorphism with UC or CD in the East Asian population and the
Turkish population.
Conclusion: AlaAla genotype may be a protective factor in the European Caucasian population against the development of
CD in a recessive way.
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Introduction
Inflammatory bowel disease (IBD) clinically classified into
ulcerative colitis (UC) and Crohn `s disease (CD) is a non specific
chronic intestinal inflammatory disorder with the characteristics of
relapses and remissions. When diagnosed, patients with UC or CD
need lifelong medications. Moreover, strictures, abscesses, fistulas,
extra intestinal involvements and even carcinomas would
complicate IBD and eventually affect the progression of IBD. In
the last three decades, we have witnessed a time trend increase of
the prevalence of IBD especially of CD both in developed and
developing regions [1].
Although the treatment of IBD has advanced considerably and
guidelines have just been revised, IBD is still incurable [2].
Clarifying the etiology of IBD may help us to find optimal
therapies. To date, it is believed that the inappropriate response of
the intestinal mucosal immune system to indigenous intestinal flora
and other antigens is crucial in IBD development [3]. The
mechanism of the inappropriate response is different in UC and
CD. The deficiency of the innate immune system which permits
intestinal pathogens to break through the intestinal barrier and
activate the adaptive immune system may be responsible for the
uncontrolled inflammation in CD, while UC is probably caused by
the primarily upregulated response of the intestinal mucosal
immune system [4].
Peroxisome proliferator-activated receptor gamma (PPARc), a
nuclear receptor, has been implicated as playing some role in the
development of UC and CD [5,6]. One experimental study even
showed the beneficial effect of a PPARc agonist on UC [7]. The
CCA-to-GCA (Pro-to-Ala) mutation in codon 12 of exon B of the
PPARc2 is a common single nucleotide polymorphism (SNP) [8].
The Pro12Ala mutation may affect the activity of PPARc in
epithelial cells and immunocytes, and consequently interfere with
the susceptibility of a host to develop IBD. In order to elucidate
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30551the association between the Pro12Ala mutation and the
development of IBD, some molecular epidemiological researches
were conducted worldwide. One case-control study conducted in
Japan indicated that the Pro12Ala mutation was more frequently
found in UC patients [9]. Another study showed a significant
association between this mutation and the development of CD
[10]. However, a research conducted in China and Holland
failed to confirm the association between the Pro12Ala
polymorphism and IBD [11]. One reason of the inconsistent
results of previous studies may be the sample size not large
enough in some studies. Meta-analysis is a well-established
method combining all available published data to increase the
statistical power of the analysis. Hence we performed this meta-
analysis to determine whether the Pro12Ala mutation was
associated with the development of IBD.
Methods
Searching strategies
PubMed (1966 to June 2011) and Scopus (1966 to June 2011)
were searched using the combinations of text words and medical
subject headings (MeSH) including ‘‘inflammatory bowel disease’’,
‘‘ulcerative colitis’’, ‘‘Crohn’s disease’’, ‘‘IBD’’, ‘‘UC’’, ‘‘CD’’,
‘‘peroxisome proliferator-activated receptor’’, ‘‘PPAR’’, ‘‘polymor-
phism’’, ‘‘polymorphisms’’, ‘‘single nucleotide’’, ‘‘allele’’ and
‘‘genotype’’. Chinese medical databases including Wanfang
database (1982 to June 2011), China National Knowledge
Infrastructure (CNKI, 1994 to June 2011) and Chinese Biomedical
Literature Database (CBM, 1978 to June 2011) were also searched
for relevant articles. We searched reference lists, relevant meta-
analyses and reviews in order to get additional articles.
Study selection criteria
The following selection criteria were employed in this meta-
analysis: 1) Case-control studies evaluating the association between
the PPARc2 Pro12Ala mutation and the presence of IBD. 2)
Diagnosis of IBD according to clinical manifestations, radiological
changes, endoscopic manifestations, and histological evaluations
comprehensively. 3) Hardy-Weinberg equilibrium fulfilled in the
control arm of each research. 4) Articles with a full text not just an
abstract. 5) Articles providing raw data or Odds ratio (OR) and its
95% confidence interval (CI) for each comparison. Exclusion
criteria were as the follows: 1) Repetitive publications. 2) Family
based case-control studies.
Data extraction
Two reviewers screened the titles and abstracts of potentially
relevant articles. And the full texts of highly relevant articles would
be thoroughly read by two reviewers. When a discrepancy was
encountered, a third reviewer would be referred to and the
decision would be made through discussions. Publication year,
region the study was conducted in, ethnicity, available allele and
genotype frequencies in each arm and the method of polymor-
phism assessment of each study were exacted.
Assessment of the risks of bias
We also assessed the potential risks of bias with the items
including 1) Selection bias (differential selections of cases and
controls; selections based on UC or CD severity), 2) Information
bias (quality control measures in the genotyping process, blinding
of laboratory personnel or researchers and phenotype miscla-
ssification) and 3) confounding factors (cases and controls
matching).
Data analysis
Hardy-Weinberg equilibrium was assessed using the x2 test.
Paired combinations of genotypes were employed to determine the
hereditary models: 1) an allelic analysis (Pro vs Ala); 2) a genotypic
analysis (ProPro vs AlaAla, ProPro vs ProAla, ProAla vs AlaAla)
and 3) another genotypic analysis comparing each genotype with
the other two (Pro homozygotes vs Ala positives, Pro positives vs
Ala homozygotes, heterozygotes vs all homozygotes). If the
comparisons of ProPro vs AlaAla, ProPro vs ProAla and Pro
homozygotes vs Ala positives were statistically significant, the Ala
allele would be a dominant allele. If the comparisons of ProPro vs
AlaAla, ProAla vs AlaAla and Pro positives vs Ala homozygotes
were statistically significant, the Ala allele would be a recessive
allele. OR and its 95% CI were calculated with the methods
recommended by the Cochrane Collaboration, and a fixed value
of 0.5 was added to all cells of study results tables where no events
were observed in one or both groups [12]. The Cochrane Q x2
test and the CI overlapping status of each selected study were used
to detect the heterogeneity among studies. The I
2 statistics was also
used to evaluate the risks of heterogeneity among studies: 0%–
40% represented no risk of heterogeneity, 30%–60% represented
a low risk of heterogeneity, 50%–90% represented substantial
heterogeneity and 75%–100% represented considerable heteroge-
neity [12]. If the P value was more than 0.1, the I
2 statistics
indicating no or a low risk of heterogeneity and the CI of each
study overlapped, a fixed model was employed and the Mantel-
Haenszel method was implemented to synthesize data. If the P
value was less than 0.1, the I
2 statistics indicating substantial or
considerable heterogeneity or the CI of each study did not
overlapped, a random model was employed and the DerSimonian-
Laird method was applied to synthesize data. Funnel plots were
used to examine bias in the results of the meta-analyses [13,14].
The step down Bonferroni method was used for the multiple
comparison adjustments [15]. Stata 11.0 software (StataCorp LP,
College Station, Texas, USA) was used for meta-analyses and
Hardy-Weinberg equilibrium tests. R 2.13.0 software (The R
Foundation for Statistical Computing, http://cran.csdb.cn/) was
used for the step down Bonferroni adjustments (Bon). Values of
P,0.05 were considered statistically significant. All the above
methods had been used for pooling data in two previous published
genetic association meta-analyses [16.17].
Results
Characteristics of selected studies
91 articles were identified during premature searches with our
searching strategy of the five databases (PubMed: 30; Scopus: 56;
Wanfang database: 2; CNKI: 1; CBM: 2). 59 articles were
retrieved after excluding overlapping studies. After excluding
reviews, animal studies, comments, letters and studies not
evaluating IBD, 16 studies assessing the association between the
PPARc polymorphism and IBD were found. Among the
remaining 16 articles, 8 studies did not evaluate the Pro12Ala
mutation and one republication was identified. Only 7 articles met
our selection criteria. After searching reference lists, relevant meta-
analyses and reviews, we did not find additional studies. The
selection process is illustrated in Figure 1. These 7 studies
including 1002 UC cases, 1090 CD cases and 1983 controls were
involved in this meta-analysis [9–11,18–21]. Among the selected
researches, 3 studies were conducted in the European Caucasian
population, 3 studies were conducted in the East Asian population
and one study was conducted in the Turkish population. The
control arm of each study conformed to the Hardy-Weinberg
equilibrium. The characteristics of selected studies are illustrated
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S1. The detailed searching process of Scopus is demonstrated in
Text S2.
Assessment of the risks of bias
Selection bias: Cases were selected from diagnosed UC and CD
patients in medical institutions in all the included studies. 3 studies
recruited healthy blood donors as controls [10,20,21]. One study
recruited healthy medical staff as controls [11]. While the other 3
studies only described healthy subjects as controls. Only one study
used colonoscopyto exclude IBD inthe controls[9].Only onestudy
described the severity of cases, which was mild to moderate [20].
Information bias: 3 studies used polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) as the
single nucleotide polymorphism (SNP) detection method [11,19,
20]. Mutagenically separated polymerase chain reaction (MS-
PCR) was employed by one study to detect SNP [18]. Two studies
used Taqman SNP genotyping assays (Taqman) to detect SNP
[10,21]. One study detected SNP with real time polymerase chain
reaction (RT-PCR) [9]. Investigators were blinded to data in two
studies [19,21]. Negative and positive controls were processed with
each batch of samples and all experiments were repeated twice to
ensure consistency for quality control purposes in one study [11].
One study genotyped 10% of the samples again to confirm
reproducibility [21]. No phenotype misclassification was reported
in the selected studies.
Confounding factors: Age and gender distribution were compa-
rable among arms in most studies, while controls were slightly older
as compared to CD patients in one study [20]. Regarding the
possible influence of the Pro12Ala polymorphism in PPARc2g e n e
on the risk of development of the type 2 diabetes mellitus, one study
excluded diabetics from the study and control groups [18].
Meta-analysis
The CI overlapping status, Cochrane Q x2 tests, I
2 statistics and
the detailed meta-analysis results are shown in Figure 2 and
Figure 3.
Meta-analysis in the overall population
The association between the PPARc Pro12Ala polymorphism
and UC was investigated in 6 studies with 1002 UC cases and
Figure 1. Flow diagram of the study selection process.
doi:10.1371/journal.pone.0030551.g001
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tion between this polymorphism and UC in the overall population
(Pro vs Ala: OR=0.884, 95%CI=0.625–1.251, P=0.486,
Bon=1.000; ProPro vs ProAla: OR=1.088, 95%CI=0.883–
1.340, P=0.429, Bon=1.000; ProPro vs AlaAla: OR=0.644,
95%CI=0.347–1.197, P=0.165, Bon=1.000; ProAla vs AlaAla:
Table 1. Characteristics of included studies evaluating the association between the PPARc Pro12Ala mutation and the presence of
IBD.
Author Year Location Ethnicity Case and control selection SNP method
Atug O [18] 2008 Turkey Turkish Case: patients diagnosed in medical institutions MS-PCR
Control: healthy volunteers matched for age and gender
Wang F [19] 2008 Japan East Asian Case: patients diagnosed in medical institutions PCR-RFLP
Control: healthy control subjects without detailed descriptions of
matching methods
Ferreira P [20] 2010 Portugal European Caucasian Case: patients diagnosed in medical institutions PCR-RFLP
Control: healthy blood donors without detailed descriptions of
matching methods
Shrestha UK [11] 2010 China East Asian Case: patients diagnosed in medical institutions PCR-RFLP
Control: healthy controls matched for age and gender
Andersen V [21] 2011 Denmark European Caucasian Case: patients diagnosed in medical institutions Taqman
Control: healthy blood donors without detailed descriptions of
matching methods
Aoyagi Y [9] 2010 Japan East Asia Case: patients diagnosed in medical institutions RT-PCR
Control: healthy controls matched for age and gender
Poliska S [10] 2011 Hungary European Caucasian Case: patients diagnosed in medical institutions Taqman
Control: healthy controls matched for age and gender
SNP: single nucleotide polymorphism; MS-PCR: mutagenically separated polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length
polymorphism; Taqman: Taqman SNP genotyping assays; RT-PCR: real time polymerase chain reaction.
doi:10.1371/journal.pone.0030551.t001
Table 2. Allele and genotype frequencies of the arms of included studies evaluating the association between the PPARc Pro12Ala
mutation and the presence of IBD.
Author Arms Pro Ala Pro/Pro Pro/Ala Ala/Ala HWE test
Atug O [18] UC (n=45) 83 7 38 7 0
CD (n=69) 127 11 58 11 0
Control (n=100) 187 13 87 13 0 P=0.487
Wang F [19] UC (n=118) 231 5 113 5 0
Control (n=142) 277 7 135 7 0 P=0.763
Ferreira P [20] CD (n=90) 163 17 74 15 1
Control (n=116) 209 23 95 19 2 P=0.371
Shrestha UK [11] UC (n=212) 400 24 189 22 1
CD (n=32) 61 3 29 3 0
Control(n=220) 416 24 198 20 2 P=0.079
Andersen V [21] UC (n=495) 844 146 364 116 15
CD (n=327) 564 90 240 84 3
Control (n=779) 1315 243 549 217 13 P=0.105
Aoyagi Y [9] UC (n=29) 52 6 25 2 2
CD (n=10) 20 0 10 0 0
Control (n=134) 264 4 130 4 0 P=0.861
Poliska S [10] UC (n=103) 178 28 77 24 2
CD (n=562) 990 134 433 124 5
Control (n=492) 854 130 375 104 13 P=0.083
UC: ulcerative colitis; CD: Crohn’s disease; HWE test: Hardy-Weinberg equilibrium test.
doi:10.1371/journal.pone.0030551.t002
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homozygotes vs Ala positives: OR=0.968, 95%CI=0.727–
1.289, P=0.823, Bon=1.000; Pro positives vs Ala homozygotes:
OR=0.625, 95%CI=0.337–1.159, P=0.136, Bon=0.952;
heterozygotes vs all homozygotes: OR=0.910, 95%CI=
0.739–1.120, P=0.372, Bon=1.000). Between-study heteroge-
neity was detected in the contrasts of Pro vs Ala and Pro
homozygotes vs Ala positives. The association between the
PPARc Pro12Ala polymorphism and CD was investigated in 6
studies with 1090 CD cases and 1841 controls [9–11,18,20,21].
No significant association between this polymorphism and CD in
the overall population was found either (Pro vs Ala: OR=1.117,
95%CI=0.941–1.325, P=0.204, Bon=1.000; ProPro vs Pro-
Ala: OR=1.024, 95%CI=0.845–1.242, P=0.807, Bon=
1.000; ProPro vs AlaAla: OR=1.918, 95%CI=0.938–3.922,
P=0.074, Bon=0.518; ProAla vs AlaAla: OR=1.986,
95%CI=0.953–4.139, P=0.067, Bon=0.469; Pro homozygotes
vs Ala positives: OR=1.075, 95%CI=0.890–1.297, P=0.454,
Bon=1.000; Pro positives vs Ala homozygotes: OR=1.906,
95%CI=0.933–3.893, P=0.077, Bon=0.539; heterozygotes vs
all homozygotes: OR=0.991, 95%CI=0.818–1.201, P=0.927,
Bon=1.000). Between-study heterogeneity was not detected in
all the contrasts.
Analysis in the European Caucasian population
The association between the PPARc Pro12Ala polymorphism
and UC in the European Caucasian population was investigated in
2 studies with 598 UC cases and 1271 controls [10,21]. There was
no significant association between the Pro12Ala polymorphism
and UC in the European Caucasian population (Pro vs Ala:
OR=1.047, 95%CI=0.858–1.277, P=0.651, Bon=1.000; Pro-
Pro vs ProAla: OR=1.157, 95%CI=0.917–1.459, P=0.219,
Bon=1.000; ProPro vs AlaAla: OR=0.680, 95%CI=0.346–
1.335, P=0.263, Bon=1.000; ProAla vs AlaAla: OR=0.586,
95%CI=0.293–1.173, P=0.131, Bon=0.917; Pro homozygotes
vs Ala positives: OR=1.109, 95%CI=0.886–1.388, P=0.365,
Bon=1.000; Pro positives vs Ala homozygotes: OR=0.653,
95%CI=0.334–1.280, P=0.215, Bon=1.000; heterozygotes vs
all homozygotes: OR=0.854, 95%CI=0.678–1.077, P=0.183,
Bon=1.000). Between-study heterogeneity was not detected in all
the contrasts. The association between the PPARc Pro12Ala
polymorphism and CD in the European Caucasian population
was investigated in 3 studies with 979 CD cases and 1387 controls
[10,20,21]. The AlaAla genotype seemed to protect the European
Caucasian population against the development of CD in a
recessive way(Pro vs Ala: OR=1.135, 95%CI=0.951–1.354,
P=0.162, Bon=1.000; ProPro vs ProAla: OR=1.042,
Figure 2. Forest plots for meta-analyses of the association between the PPARc Pro12Ala mutation and the presence of UC.
doi:10.1371/journal.pone.0030551.g002
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OR=2.379, 95%CI=1.110–5.100, P=0.026, Bon=0.156;
ProAla vs AlaAla: OR=2.315, 95%CI=1.064–5.037, P=0.034,
Bon=0.204; Pro homozygotes vs Ala positives: OR=1.094,
95%CI=0.899–1.330, P=0.371, Bon=1.000; Pro positives vs
Ala homozygotes: OR=2.360, 95%CI=1.103–5.053, P=0.027,
Bon=0.162; heterozygotes vs all homozygotes: OR=0.976,
95%CI=0.799–1.192, P=0.809, Bon=1.000). Between-study
heterogeneity was not detected in all the contrasts.
Analysis in the East Asian population
The association between the PPARc Pro12Ala polymorphism
and UC in the East Asian population was investigated in 3 studies
with 359 UC cases and 496 controls [9,11,19]. There was no
significant association between this polymorphism and UC in the
East Asian population (Pro vs Ala: OR=0.576, 95%CI=0.180–
1.844, P=0.353, Bon=1.000; ProPro vs ProAla: OR=0.856,
95%CI=0.502–1.460, P=0.568, Bon=1.000; ProPro vs AlaAla:
OR=0.490, 95%CI=0.089–2.700, P=0.413, Bon=1.000; ProAla
vs AlaAla: OR=0.774, 95%CI=0.128–4.669, P=0.780, Bon=
1.000; Pro homozygotes vs Ala positives: OR=0.686, 95%CI=
0.284–1.654, P=0.401, Bon=1.000; Pro positives vs Ala homozy-
gotes: OR=0.500, 95%CI=0.091–2.750, P=0.425, Bon=1.000;
heterozygotes vs all homozygotes: OR=1.164, 95%CI=0.683–
1.984, P=0.577, Bon=1.000). Between-study heterogeneity was
detected in the contrasts of Pro vs Ala and Pro homozygotes vs Ala
positives. The association between the PPARc Pro12Ala polymor-
phism and CD in the East Asian population was investigated in 2
studies with 42 CD cases and 354 controls [9,11].There was no
significant association between this polymorphism and CD in the
East Asian population (Pro vs Ala: OR=1.086, 95%CI=0.349–
3.382, P=0.886, Bon=1.000; ProPro vs ProAla: OR=0.933,
95%CI=0.289–3.012, P=0.907, Bon=1.000; ProPro vs AlaAla:
OR=0.324, 95%CI=0.029–3.663, P=0.363, Bon=1.000; ProAla
vs AlaAla: OR=0.458, 95%CI=0.031–6.825, P=0.571, Bon=
1.000; Pro homozygotes vs Ala positives: OR=1.011, 95%CI=
0.315–3.249, P=0.985, Bon=1.000; Pro positives vs Ala homozy-
gotes: OR=0.321, 95%CI=0.028–3.623, P=0.358, Bon=1.000;
heterozygotes vs all homozygotes: OR=1.082, 95%CI=0.335–
3.493, P=0.896, Bon=1.000). Between-study heterogeneity was
not detected in all the contrasts.
Analysis in the Turkish population
The association between the PPARc Pro12Ala polymorphism
and IBD in the Turkish population was investigated in 1 study
with 45 UC cases, 69 CD cases and 100 controls [18]. And this
study showed no significant association between this polymor-
phism and UC or CD in the Turkish population.
Figure 3. Forest plots for meta-analyses of the association between the PPARc Pro12Ala mutation and the presence of CD.
doi:10.1371/journal.pone.0030551.g003
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when we used a fixed model and a random model to perform our
meta-analysis respectively.
Evaluation of reporting bias
Obvious asymmetry was revealed by the shapes of the Begg
funnel plots in the overall UC analysis and the overall CD analysis.
The study with the smallest sample size reported by Aoyagi was a
clear outlier which might be suggestive of a small-study effect. The
Begg funnel plots corresponding to the allelic analysis are shown in
Figure 4.
Discussion
The core pathophysiological process of UC is the uncontrolled
inflammation mainly affecting the colon. Environmental factors
including commensal flora and other antigens and host factors
including genetic dispositions are all involved in the UC
development [3,4]. The primarily upregulated response of the
intestinal mucosal immune system is probably responsible for the
uncontrolled inflammation of UC [4].
Firstly, dysfunction of the cellular and immune intestinal barrier
which separates the microbial flora from host tissues renders a host
susceptible to invasive factors [22]. Secondly, environmental
factors including the dietary factor and microbia activate the
Toll-like receptors (TLRs), which then activate NF-kB and cause
the expression of pro-inflammatory genes consequently [23]. In
the inflammation regulation networks, activation of PPARc could
suppress the activation of NFkB and TLRs [24,25], therefore
inhibit the cascades of inflammation. Decreased PPARc expres-
sion in epithelial cells was also found in UC patients in one study
[26]. Moreover, a randomized placebo-controlled trial suggested
that a PPARc agonist was efficacious in the treatment of mild to
moderately active UC [27]. All of these indicate normal expression
of PPARc as a protecting factor against the development of UC.
Pro12Ala mutation is a common mutation, which downregulates
the activity of PPARc as indicated in one study [28]. Therefore the
Pro12Ala mutation may be a risk factor for UC. However, our
meta-analysis did not find a significant association between this
mutation and the development of UC in the overall, European
Caucasian and East Asian population. Our explanation is that the
Pro12Ala mutation only affects the function of PPARc2, and the
function of PPARc1 which makes up a large portion of PPARc in
intestines is intact. So the effect of the Pro12Ala mutation on the
whole PPARc function is limited, which would attenuate the effect
of the Pro12Ala mutation on UC.
The mechanism of the uncontrolled inflammation in CD is
different from that in UC. The deficiency of the innate immune
system which permits intestinal pathogens to break through the
intestinal barrier and activates the adaptive immune system may
be responsible for the uncontrolled inflammation in CD [4]. The
impaired function of macrophages may be the central process in
the innate immune system deficiency [4,29,30], which causes
granulomas in CD consequently. Nod proteins and PPARc are all
involved in the maintenance of normal innate immune system
[6,31]. Gene mutations of the elements constituting the innate
immune system may contribute to the CD development. Genetics
play more important roles in the development of CD than in the
development of UC [32,33]. NOD2/CARD15 polymorphism is
the first confirmed risk factor for CD in Caucasian populations
[34]. This encourages researchers to find other CD susceptible
gene polymorphisms. A recent meta-analysis of genome-wide
association scans identified PTPN2, IL18RAP, TAGAP, and PUS10
loci as new CD risk factors [35], which widened our understanding
of the gene background of CD. The PPARc Pro12Ala mutation
would decrease the function of PPARc [28], and consequently
abate its suppression on the activation of NFkB and TLRs [24,25],
which would enhance the function of the innate immune system
and protect a host against the development of CD.
Our meta-analysis supports this hypothesis. The AlaAla
genotype seemed to protect the European Caucasian population
against the development of CD. The Pro12Ala mutation only
affects the function of PPARc2, which supports PPARc2a sa
modulator in the innate immune system maintenance. However,
we did not find an association between this polymorphism and CD
in the East Asian population. This is in consistence with the
observation of NOD2/CARD15 polymorphism on CD in the non
Caucasian populations [36,37]. We deduce that the PPARc
Pro12Ala mutation, the NOD2/CARD15 polymorphism and
other unknown gene polymorphisms mainly occurred in the
Caucasian population may function synergistically in the CD
development. Further these polymorphisms may constitute the
gene background of the Caucasian population in turn.
However, the conclusions of this meta-analysis should be
interpreted cautiously. This meta-analysis has some limitations.
Firstly, only one study used colonoscopy to exclude IBD in the
controls [9]. Only one study described the severity of cases, which
was mild to moderate [20]. All of the above could cause selection
Figure 4. Begg funnel plots of the overall UC analysis and the overall CD analysis.
doi:10.1371/journal.pone.0030551.g004
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measures for genotyping quality control [11,21], and two studies
used blindness measures [19,21]. Information bias could not be
excluded completely. Thirdly, the controls were slightly older as
compared to CD patients in one study [20], which would affect the
comparability between arms in this study. Fourthly, the number of
included studies was not large enough although we endeavored to
collect relevant full text published studies. Fifthly, Obvious
asymmetry was revealed by the shapes of the Begg funnel plots
in the overall UC analysis and the overall CD analysis. The study
with the smallest sample size reported by Aoyagi was a clear
outlier, which might be suggestive of a small-study effect. Thus a
reporting bias cannot be excluded. More high quality and large
sample studies evaluating the association between the Pro12Ala
mutation and the presence of IBD are still needed. An update of
our meta-analysis is necessary in the future. Furthermore, only one
study evaluated the interaction between diets and the Pro12Ala
polymorphism which showed that a high intake of saturated and
mono-unsaturated fat was associated with a more active CD only
in wild type carriers [20]. The combined effect of diets and this
polymorphism still needs to be elucidated. Studies investigating the
interaction between the PPARc Pro12Ala mutation and the
NOD2/CARD15 polymorphism in the CD development in the
Caucasian population are also wanted.
In conclusion, based on published full text case-control studies,
our meta-analysis demonstrates that the AlaAla genotype may be a
protecting factor in the European Caucasian population against
the development of CD in a recessive way.
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